Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Pfizer
Grange Castle

Pfizer cancels €400m expansion at Dublin plant

The plan was dependent on the success of a new cholesterol-reducing drug.

PFIZER HAS CANCELLED a planned €400 million expansion at its Grange Castle plant in Clondalkin, Dublin.

The pharmaceutical company didn’t formally announce the investment, but recently sought planning permission for the development of the site.

In a statement it said the proposal was dependent on the success of clinical trials of bococizumab, a cholesterol-reducing drug.

The extension would have created 350 permanent jobs and over 1,000 roles during construction.

Grange Castle Grange Castle Pfizer Pfizer

A spokesperson for Pfizer said: “Following the decision to discontinue the development of bococizumab, part of the potential expansion for which the planning permission was sought will not now go ahead.

Expansion in relation to other incoming products will continue as planned involving investment, recruitment and new technology.

“Current and future development at Grange Castle, which is one of Pfizer’s leading biotechnology sites manufacturing a broad portfolio of biologic medicines and vaccines, is based on a number of commercialised products and pipeline compounds.”

Pfizer employs more than 3,000 people at plants in Dublin, Kildare, Cork and Sligo.

Read: Fine Gael is most popular party as Fianna Fáil loses ground

Read: Top Irish PR body seeks to curb rogue ‘influencers’ being paid to sell products and not admitting it

Your Voice
Readers Comments
41
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.